Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model

Prashant Chandrasekharan; Chang Tong Yang; Fatima Ali Nasrallah; Hui Chien Tay; Kai Hsiang Chuang; Edward G. Robins

doi:10.1002/cmmi.1634

Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model

Prashant Chandrasekharan, Chang Tong Yang, Fatima Ali Nasrallah, Hui Chien Tay, Kai Hsiang Chuang, Edward G. Robins

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Pharmacokinetics of Gd(DO3A-Lys), a macrocyclic gadolinium-based magnetic resonance imaging (MRI) contrast agent functionalized with a lysine derivative, was studied in Wistar rats. Kinetic data were fitted using a two-compartment model and revealed Gd(DO3A-Lys) to have a distribution half-life, t_1/2(α), of 1.3min, an elimination half-life, t_1/2(β), of 24.9min and a large volume of distribution, V_D, of 0.49L/kg indicative of the agent being able to rapidly distribute into tissues and organs. Contrast-enhanced magnetic resonance angiography (CE-MRA) in an orthotopic U87MG glioma mouse model demonstrated considerable enhancement of both the tumor and surrounding vasculature after intravenous administration of Gd(DO3A-Lys). Applying dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the glioma of different sizes further showed distinct uptake characteristics and patterns of enhancement, which suggests the potential for differentiating changes at different stages of tumor growth. Our results indicate that Gd(DO3A-Lys) could be a promising candidate for glioma MR imaging.

Original language	English
Pages (from-to)	237-244
Number of pages	8
Journal	Contrast Media and Molecular Imaging
Volume	10
Issue number	3
DOIs	https://doi.org/10.1002/cmmi.1634
Publication status	Published or Issued - 1 May 2015
Externally published	Yes

Keywords

Contrast agent
Gadolinium chelate
Magnetic resonance imaging (MRI)
Orthotopic glioma model
Pharmacokinetics
Tumor diagnosis

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1002/cmmi.1634

Cite this

@article{38008ad6c106402086f67dd438829719,

title = "Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model",

abstract = "Pharmacokinetics of Gd(DO3A-Lys), a macrocyclic gadolinium-based magnetic resonance imaging (MRI) contrast agent functionalized with a lysine derivative, was studied in Wistar rats. Kinetic data were fitted using a two-compartment model and revealed Gd(DO3A-Lys) to have a distribution half-life, t1/2(α), of 1.3min, an elimination half-life, t1/2(β), of 24.9min and a large volume of distribution, VD, of 0.49L/kg indicative of the agent being able to rapidly distribute into tissues and organs. Contrast-enhanced magnetic resonance angiography (CE-MRA) in an orthotopic U87MG glioma mouse model demonstrated considerable enhancement of both the tumor and surrounding vasculature after intravenous administration of Gd(DO3A-Lys). Applying dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the glioma of different sizes further showed distinct uptake characteristics and patterns of enhancement, which suggests the potential for differentiating changes at different stages of tumor growth. Our results indicate that Gd(DO3A-Lys) could be a promising candidate for glioma MR imaging.",

keywords = "Contrast agent, Gadolinium chelate, Magnetic resonance imaging (MRI), Orthotopic glioma model, Pharmacokinetics, Tumor diagnosis",

author = "Prashant Chandrasekharan and Yang, {Chang Tong} and Nasrallah, {Fatima Ali} and Tay, {Hui Chien} and Chuang, {Kai Hsiang} and Robins, {Edward G.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons, Ltd.",

year = "2015",

month = may,

day = "1",

doi = "10.1002/cmmi.1634",

language = "English",

volume = "10",

pages = "237--244",

journal = "Contrast Media and Molecular Imaging",

issn = "1555-4309",

number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model

AU - Chandrasekharan, Prashant

AU - Yang, Chang Tong

AU - Nasrallah, Fatima Ali

AU - Tay, Hui Chien

AU - Chuang, Kai Hsiang

AU - Robins, Edward G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Pharmacokinetics of Gd(DO3A-Lys), a macrocyclic gadolinium-based magnetic resonance imaging (MRI) contrast agent functionalized with a lysine derivative, was studied in Wistar rats. Kinetic data were fitted using a two-compartment model and revealed Gd(DO3A-Lys) to have a distribution half-life, t1/2(α), of 1.3min, an elimination half-life, t1/2(β), of 24.9min and a large volume of distribution, VD, of 0.49L/kg indicative of the agent being able to rapidly distribute into tissues and organs. Contrast-enhanced magnetic resonance angiography (CE-MRA) in an orthotopic U87MG glioma mouse model demonstrated considerable enhancement of both the tumor and surrounding vasculature after intravenous administration of Gd(DO3A-Lys). Applying dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the glioma of different sizes further showed distinct uptake characteristics and patterns of enhancement, which suggests the potential for differentiating changes at different stages of tumor growth. Our results indicate that Gd(DO3A-Lys) could be a promising candidate for glioma MR imaging.

AB - Pharmacokinetics of Gd(DO3A-Lys), a macrocyclic gadolinium-based magnetic resonance imaging (MRI) contrast agent functionalized with a lysine derivative, was studied in Wistar rats. Kinetic data were fitted using a two-compartment model and revealed Gd(DO3A-Lys) to have a distribution half-life, t1/2(α), of 1.3min, an elimination half-life, t1/2(β), of 24.9min and a large volume of distribution, VD, of 0.49L/kg indicative of the agent being able to rapidly distribute into tissues and organs. Contrast-enhanced magnetic resonance angiography (CE-MRA) in an orthotopic U87MG glioma mouse model demonstrated considerable enhancement of both the tumor and surrounding vasculature after intravenous administration of Gd(DO3A-Lys). Applying dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the glioma of different sizes further showed distinct uptake characteristics and patterns of enhancement, which suggests the potential for differentiating changes at different stages of tumor growth. Our results indicate that Gd(DO3A-Lys) could be a promising candidate for glioma MR imaging.

KW - Contrast agent

KW - Gadolinium chelate

KW - Magnetic resonance imaging (MRI)

KW - Orthotopic glioma model

KW - Pharmacokinetics

KW - Tumor diagnosis

UR - http://www.scopus.com/inward/record.url?scp=84930925137&partnerID=8YFLogxK

U2 - 10.1002/cmmi.1634

DO - 10.1002/cmmi.1634

M3 - Article

C2 - 25612157

AN - SCOPUS:84930925137

SN - 1555-4309

VL - 10

SP - 237

EP - 244

JO - Contrast Media and Molecular Imaging

JF - Contrast Media and Molecular Imaging

IS - 3

ER -

Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this